Allergy Therapeutics (AGY) Stock Rating Reaffirmed by Numis Securities
Allergy Therapeutics (LON:AGY)‘s stock had its “buy” rating restated by equities research analysts at Numis Securities in a report issued on Wednesday.
Separately, FinnCap reaffirmed a “corporate” rating on shares of Allergy Therapeutics in a research report on Thursday, July 12th.
LON AGY opened at GBX 24.50 ($0.32) on Wednesday. Allergy Therapeutics has a 1 year low of GBX 23 ($0.30) and a 1 year high of GBX 39.50 ($0.51).
Allergy Therapeutics plc, a specialty pharmaceutical company, focuses on allergy vaccination primarily in Europe. The company's primary flagship product is the Pollinex Quattro for the treatment of allergic conditions. It offers monophosphoryl-lipid A, a substance that enhances the immune response to an antigen or allergen; sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; and synbiotics that are special formulations of prebiotics and probiotics, such as Kallergen-Th, ATI Prob, and Pollagen.
Recommended Story: Price to Earnings Ratio (PE)
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.